Senior Software Engineer, Asimov
$160-175k
Intelligent genetic design platform
Be an early applicant
Intelligent genetic design platform
21-100 employees
Be an early applicant
$160-175k
21-100 employees
Company mission
To empower the genetic designers who are building the future.
Role
Who you are
- You have 6+ years building production software - systems that other engineers depend on, not research code that runs once
- You have expertise in Python 3 and ideally experience with GraphQL, SQLAlchemy, and/or Strawberry
- You’re the kind of engineer who loses track of time working on an interesting technical problem. You want challenges that will have you waking up with a new idea that you can’t wait to try
- You want to help design a product with a close-knit team, not just write code from predefined specifications. You can navigate the ambiguity of building something first-of-its-kind
What the job involves
- Genetic engineering will be even more demanding—and we're building the tools to make it possible. Kernel is our platform for bioengineers to design, build, and debug genetic systems as confidently as we ship code. We're looking for a Senior Software Engineer to help us build it
- You'll join an interdisciplinary team that works directly with scientists, synthetic biologists, and computational biologists alongside your teammates in software engineering and product
- Design GraphQL APIs for searching, editing and analyzing tens of thousands of genetic constructs using Python 3, SQLAlchemy and Strawberry
- Shape the software architecture and be involved in the long-term product direction.Collaborate on data models that represent the genuine complexity of biological systems
- Interface directly with synthetic biologists to understand their workflows and identify tools that would transform their productivity
- Be part of an on-call rotation to support the software you’ve helped develop
Our take
Despite the many recent breakthroughs in medicine, drug manufacturing remains a lengthy and costly process that is difficult to scale. Asimov seeks to combat this with its intelligent design suite for synthetic biologists, that leverages computer-aided design to help design, simulate, and optimise genetic systems more reliably.
Asimov's platform consists of a fully integrated suite of cells, genes, and software that can be implemented in every step of the therapeutics creation process from initial design through to analysis. By accelerating the speed at which biologists can test and improve their drugs, the company hopes to help bring innovative treatments to market faster and thus advance the standard of treatment for patients.
Having secured considerable funding, Asimov is looking to scale its business in biologics, advanced cell/gene therapies, and RNA. It will also use the investment to expand research and development into new areas of synthesis, as well as grow its team.
Steph
Company Specialist at Welcome to the Jungle
Company
Funding (last 2 of 3 rounds)
Jan 2023
$175m
SERIES B
Dec 2019
$25m
SERIES A
Total funding: $204.7m
Company HQ
West Fens, Boston, MA
Leadership
Chris Voigt
(Co-Founder)Board Member at the Novo Nordisk Foundation, MIT Professor, and Co-Founder of Pivot Bio.
Douglas Densmore
(Co-Founder)Professor at Boston University. Previously co-founded BioSens8 and Lattice Automation.
Salary benchmarks
We don't have enough data yet to provide salary benchmarks for this role.
Submit your salary to help other candidates with crowdsourced salary estimates.
Share this job
View 1 more job at Asimov